Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887083 | 0.87 | SMN1; SMN2 (0.47) | CYP11B1CYP11B2KMT2ANAPRTGAA | |
| SCHEMBL10630143 | 0.83 | FAAH (0.45) | CYP11B1CYP11B2KMT2AATMSMN1; SMN2 | |
| SCHEMBL2273651 | 0.83 | CYP11B1 (0.39) | CYP11B1CYP11B2KMT2ANAPRTP4HB | |
| SCHEMBL5214892 | 0.81 | GAA (0.40) | CYP11B1CYP11B2NAPRTGAASMN1; SMN2 | |
| SCHEMBL21831822 | 0.79 | SLC6A2 (0.44) | CYP11B1CYP11B2KMT2AP4HBATM | |
| SCHEMBL5215520 | 0.78 | KCNA5 (0.36) | NAPRTGAA | |
| SCHEMBL21831149 | 0.78 | LMNA (0.47) | KMT2AATM | |
| SCHEMBL30910897 | 0.78 | LMNA (0.47) | KMT2AATM | |
| SCHEMBL21831292 | 0.77 | ALOX5AP (0.38) | CYP11B1CYP11B2KMT2AATM | |
| SCHEMBL28857228 | 0.76 | POLB (0.42) | KMT2ANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | disclosed |
| EP-1751119-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | VIP, CCKBR, HRH2 | CYP11B1 103/4885CYP11B2 65/4885KMT2A 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.